 SHANGHAI and ROCKVILLE, Md., May 26, 2021 PRNewswire -- WuXi Biologics WuXi Bio 2269.HK, a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4s full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China. 